Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 10/20 | 0.44 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504779 | 0.86 | MAPKAPK2 (0.46) | MAPKAPK2HSD11B1CNR1NPC1ALDH1A1 | |
| SCHEMBL27657223 | 0.84 | MAPKAPK2 (0.45) | MAPKAPK2ALDH1A1BIRC5 | |
| SCHEMBL6528504 | 0.84 | HSD11B1 (0.51) | MAPKAPK2HSD11B1CNR1CNR2 | |
| SCHEMBL28302004 | 0.80 | MAPKAPK2 (0.53) | MAPKAPK2ALDH1A1LMNABIRC5 | |
| SCHEMBL14740470 | 0.79 | TP53 (0.42) | MAPKAPK2NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5594919 | 0.79 | HSD11B1 (0.51) | MAPKAPK2HSD11B1ALDH1A1RAB9A | |
| SCHEMBL5319319 | 0.78 | MAPKAPK2 (0.60) | MAPKAPK2ALDH1A1 | |
| SCHEMBL4563977 | 0.74 | HSD11B1 (0.45) | MAPKAPK2HSD11B1CNR1CNR2ALDH1A1 | |
| SCHEMBL6613702 | 0.73 | HSD11B1 (0.45) | HSD11B1CNR1CNR2NPC1ALDH1A1 | |
| SCHEMBL5751866 | 0.73 | FGFR1 (0.42) | MAPKAPK2ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | MAPKAPK2 1042/4885HSD11B1 1022/4885CNR1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.